

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Gonioscopy
PAGE: 1 of 28	REFERENCE NUMBER: OC.UM.CP.0031
EFFECTIVE DATE: 10/01/2016	REPLACES DOCUMENT: 187-UM-R2, 3064-MM-R4 Gonioscopy
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 3/20/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

IMPORTANT REMINDER

This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted standards of medical practice, peer-reviewed medical literature, government agency/program approval status, and other indicia of medical necessity.

The purpose of this Clinical Policy is to provide a guide to medical necessity. Benefit determinations should be based in all cases on the applicable contract provisions governing plan benefits (“Benefit Plan Contract”) and applicable state and federal requirements including Local Coverage Determinations (LCDs), as well as applicable plan-level administrative policies and procedures. To the extent there are any conflicts between this Clinical Policy and the Benefit Plan Contract provisions, the Benefit Plan Contract provisions will control.

Clinical policies are intended to be reflective of current scientific research and clinical thinking. This Clinical Policy is not intended to dictate to providers how to practice medicine, nor does it constitute a contract or guarantee regarding results. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members.

SUBJECT:

Medical necessity determination for performance of gonioscopy.

DESCRIPTION:

The angle of the anterior chamber of the eye is examined in a gonioscopy to assess for angle closure glaucoma, iris neovascularization, or other injury or disease process in the anterior chamber. Since the cornea's curvature creates internal reflection when the anterior angle structures are viewed directly, a gonioscopic lens is used to observe the angle. Corneal integrity is first determined using fluorescein. The patient is given anesthesia, the goniolens is prepared, and the physician places it on the patient's cornea. The lens puts a concave surface against the cornea, eliminating its refracting surface and allowing the angle to be observed with oblique mirrors. With the illumination

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Gonioscopy
PAGE: 2 of 28	REFERENCE NUMBER: OC.UM.CP.0031
EFFECTIVE DATE: 10/01/2016	REPLACES DOCUMENT: 187-UM-R2, 3064-MM-R4 Gonioscopy
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 3/20/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

lamp and microscope set and the beam oriented parallel to the axis of the mirror, the gonioscopy is accomplished and the angle of the anterior chamber of the eye is examined. The lens is removed, the eye is irrigated, and the cornea is checked again.

POLICY/CRITERIA:

Indications for gonioscopy include, but are not limited to glaucoma, hypotony, occlusive disorders, diabetic retinopathy, rubeosis, aphakia, an intraocular foreign body and a subluxated or dislocated lens. Gonioscopy of both eyes should be performed on all patients in whom angle closure is suspected to evaluate the angle anatomy, appositional closure, and presence of peripheral anterior synechia (PAS). Compression (indentation) gonioscopy with a four-mirror or similar lens is particularly helpful to determine if visible appositional closure is actually permanent, synechial closure and, if so, for the extent of such PAS. Gonioscopy should be performed in a dark room with a bright, short (approximately 1 mm in length) beam that does not pass through the pupil to avoid inducing pupillary constriction, which can widen the angle. Gonioscopic visualization of the angle may be impaired secondary to corneal edema in the setting of acute angle-closure glaucoma. Topical glycerin may be used to clear the cornea to obtain a better view.

The diagnosis of primary open angle glaucoma requires careful evaluation of the anterior chamber angle to exclude angle closure or secondary causes of intraocular pressure (IOP) elevation, such as angle recession, pigment dispersion, peripheral anterior synechiae, angle neovascularization, and inflammatory precipitates.

For primary angle closure glaucoma (ACG, ICD-10 H40.20X0-H40.243), Envolve Vision Benefits, Inc. (Envolve Vision) reimburses for gonioscopy up to four times for the first year after diagnosis (service date to service date) and up to two times per year for established cases thereafter (service date to service date).

For primary ACG acute attack (ICD-10 H40.211-H40.213), Envolve Vision reimburses for gonioscopy every 24 to 48 hours until Laser Peripheral Iridotomy

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Gonioscopy
PAGE: 3 of 28	REFERENCE NUMBER: OC.UM.CP.0031
EFFECTIVE DATE: 10/01/2016	REPLACES DOCUMENT: 187-UM-R2, 3064-MM-R4 Gonioscopy
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 3/20/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

(LPI), and then up to four times within the first year, every six months thereafter for one year, and then annually (service date to service date).

For other covered ICD-10 diagnoses, Envolve Vision will reimburse for gonioscopy up to two times per year (service date to service date).

AUTHORIZATION PROTOCOLS:

Gonioscopy is subject to retrospective medical record review.

Professional services provided by duly licensed eye care providers must be within the scope of licensure as defined by applicable State guidelines.

SCIENTIFIC BACKGROUND:

Gonioscopy is required to view the iridocorneal angle, because light from the angle reflects back into the anterior chamber at the tear-air interface. This is because of the total internal reflection—just as in a fiber optic cable. The only circumstances in which the angle can be seen without special manipulation are in cases of keratoglobus where the light from the angle strikes the cornea at an angle perpendicular enough to escape. This is very rare.

REFERENCES:

“A History of Gonioscopy”, Alward, Wallace L.M., Optometry & Vision Science: January 2011 – Volume 88 – Issue 1 – pp 29-35

American Academy of Ophthalmology Glaucoma Panel, Preferred Practice Pattern® Guidelines. Primary Open-Angle Glaucoma, San Francisco, CA: American Academy of Ophthalmology; 2015, www.aao.org/ppp

American Academy of Ophthalmology Glaucoma Panel, Preferred Practice Pattern® Guidelines. Primary Angle Closure, San Francisco, CA: American Academy of Ophthalmology; 2015, www.aao.org/ppp

Reimbursement Considerations for Gonioscopy, A Discussion of Coverage, Coding and Billing; Donna M. McCune, CCS-P, COE and Kevin J. Corcoran, COE, CPC, FNAO, Glaucoma Today, September/October 2008

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Gonioscopy
PAGE: 4 of 28	REFERENCE NUMBER: OC.UM.CP.0031
EFFECTIVE DATE: 10/01/2016	REPLACES DOCUMENT: 187-UM-R2, 3064-MM-R4 Gonioscopy
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 3/20/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

CODING IMPLICATIONS:

The following codes for treatment and procedures are for informational purposes only. They are current at time of review of this policy. Inclusion or exclusion of any codes does not guarantee coverage. Please refer to your State contract for exact coverage implications.

CPT code 92020 represents a bilateral service. Modifiers RT, LT, or 50 are not valid and should not be used. CPT 92020 has no technical or professional components. Modifiers TC or 26 are not valid and should not be used.

Envolve Vision follows the National Correct Coding Initiative (CCI) guidelines when processing claims for these services. If the claim is denied based upon CCI edits, an appeal must be submitted with the medical records and a dictated and signed statement from the provider clearly stating what additional information will be gleaned by multiple imaging and how these multiple images will positively impact the patient's care.

Envolve Vision follows the Multiple Procedure Payment Reduction guidelines (MPPR) when reimbursing for multiple diagnostic procedures. CCI guidelines are applied prior to MPPR.

<u>ICD-10 Code</u>	<u>ICD-10 Code Description</u>
E08.3211	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right eye
E08.3212	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, left eye
E08.3213	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, bilateral

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Gonioscopy
PAGE: 5 of 28	REFERENCE NUMBER: OC.UM.CP.0031
EFFECTIVE DATE: 10/01/2016	REPLACES DOCUMENT: 187-UM-R2, 3064-MM-R4 Gonioscopy
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 3/20/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

E08.3291	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, right eye
E08.3292	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, left eye
E08.3293	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, bilateral
E08.3311	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, right eye
E08.3312	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, left eye
E08.3313	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, bilateral
E08.3391	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, right eye
E08.3392	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, left eye
E08.3393	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, bilateral
E08.3411	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, right eye
E08.3412	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, left eye
E08.3413	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, bilateral

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Gonioscopy
PAGE: 6 of 28	REFERENCE NUMBER: OC.UM.CP.0031
EFFECTIVE DATE: 10/01/2016	REPLACES DOCUMENT: 187-UM-R2, 3064-MM-R4 Gonioscopy
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 3/20/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

E08.3491	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, right eye
E08.3492	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, left eye
E08.3493	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, bilateral
E08.3511	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, right eye
E08.3512	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, left eye
E08.3513	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, bilateral
E08.3521	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye
E08.3522	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye
E08.3523	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral
E08.3531	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye
E08.3532	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye
E08.3533	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Gonioscopy
PAGE: 7 of 28	REFERENCE NUMBER: OC.UM.CP.0031
EFFECTIVE DATE: 10/01/2016	REPLACES DOCUMENT: 187-UM-R2, 3064-MM-R4 Gonioscopy
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 3/20/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

E08.3541	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye
E08.3542	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye
E08.3543	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral
E08.3551	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, right eye
E08.3552	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, left eye
E08.3553	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, bilateral
E08.3591	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, right eye
E08.3592	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, left eye
E08.3593	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, bilateral
E08.37X1	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, right eye
E08.37X2	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, left eye
E08.37X3	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, bilateral
E09.3211	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye
E09.3212	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Gonioscopy
PAGE: 8 of 28	REFERENCE NUMBER: OC.UM.CP.0031
EFFECTIVE DATE: 10/01/2016	REPLACES DOCUMENT: 187-UM-R2, 3064-MM-R4 Gonioscopy
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 3/20/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

E09.3213	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral
E09.3291	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye
E09.3292	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye
E09.3293	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral
E09.3311	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye
E09.3312	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye
E09.3313	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral
E09.3391	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye
E09.3392	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye
E09.3393	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral
E09.3411	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye
E09.3412	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Gonioscopy
PAGE: 9 of 28	REFERENCE NUMBER: OC.UM.CP.0031
EFFECTIVE DATE: 10/01/2016	REPLACES DOCUMENT: 187-UM-R2, 3064-MM-R4 Gonioscopy
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 3/20/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

E09.3413	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral
E09.3491	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye
E09.3492	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye
E09.3493	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral
E09.3511	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye
E09.3512	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye
E09.3513	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral
E09.3521	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye
E09.3522	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye
E09.3523	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral
E09.3531	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye
E09.3532	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Gonioscopy
PAGE: 10 of 28	REFERENCE NUMBER: OC.UM.CP.0031
EFFECTIVE DATE: 10/01/2016	REPLACES DOCUMENT: 187-UM-R2, 3064-MM-R4 Gonioscopy
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 3/20/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

E09.3533	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral
E09.3541	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye
E09.3542	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye
E09.3543	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral
E09.3551	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, right eye
E09.3552	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, left eye
E09.3553	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, bilateral
E09.3591	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye
E09.3592	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye
E09.3593	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral
E09.37X1	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, right eye
E09.37X2	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, left eye
E09.37X3	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral
E10.3211	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye
E10.3212	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Gonioscopy
PAGE: 11 of 28	REFERENCE NUMBER: OC.UM.CP.0031
EFFECTIVE DATE: 10/01/2016	REPLACES DOCUMENT: 187-UM-R2, 3064-MM-R4 Gonioscopy
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 3/20/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

E10.3213	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral
E10.3291	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye
E10.3292	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye
E10.3293	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral
E10.3311	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye
E10.3312	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye
E10.3313	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral
E10.3391	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye
E10.3392	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye
E10.3393	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral
E10.3411	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye
E10.3412	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye
E10.3413	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral
E10.3491	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye
E10.3492	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye
E10.3493	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral
E10.3511	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Gonioscopy
PAGE: 12 of 28	REFERENCE NUMBER: OC.UM.CP.0031
EFFECTIVE DATE: 10/01/2016	REPLACES DOCUMENT: 187-UM-R2, 3064-MM-R4 Gonioscopy
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 3/20/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

E10.3512	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye
E10.3513	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral
E10.3521	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye
E10.3522	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye
E10.3523	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral
E10.3531	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye
E10.3532	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye
E10.3533	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral
E10.3541	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye
E10.3542	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye
E10.3543	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral
E10.3551	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, right eye
E10.3552	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, left eye
E10.3553	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Gonioscopy
PAGE: 13 of 28	REFERENCE NUMBER: OC.UM.CP.0031
EFFECTIVE DATE: 10/01/2016	REPLACES DOCUMENT: 187-UM-R2, 3064-MM-R4 Gonioscopy
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 3/20/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

E10.3591	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye
E10.3592	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye
E10.3593	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral
E10.37X1	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye
E10.37X2	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye
E10.37X3	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral
E11.3211	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye
E11.3212	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye
E11.3213	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral
E11.3291	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye
E11.3292	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye
E11.3293	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral
E11.3311	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye
E11.3312	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye
E11.3313	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral
E11.3391	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye
E11.3392	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Gonioscopy
PAGE: 14 of 28	REFERENCE NUMBER: OC.UM.CP.0031
EFFECTIVE DATE: 10/01/2016	REPLACES DOCUMENT: 187-UM-R2, 3064-MM-R4 Gonioscopy
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 3/20/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

E11.3393	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral
E11.3411	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye
E11.3412	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye
E11.3413	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral
E11.3491	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye
E11.3492	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye
E11.3493	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral
E11.3511	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye
E11.3512	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye
E11.3513	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral
E11.3521	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye
E11.3522	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye
E11.3523	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral
E11.3531	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye
E11.3532	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye
E11.3533	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Gonioscopy
PAGE: 15 of 28	REFERENCE NUMBER: OC.UM.CP.0031
EFFECTIVE DATE: 10/01/2016	REPLACES DOCUMENT: 187-UM-R2, 3064-MM-R4 Gonioscopy
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 3/20/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

E11.3541	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye
E11.3542	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye
E11.3543	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral
E11.3551	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, right eye
E11.3552	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, left eye
E11.3553	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral
E11.3591	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye
E11.3592	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye
E11.3593	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral
E11.37X1	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye
E11.37X2	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye
E11.37X3	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral
E13.3211	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye
E13.3212	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye
E13.3213	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Gonioscopy
PAGE: 16 of 28	REFERENCE NUMBER: OC.UM.CP.0031
EFFECTIVE DATE: 10/01/2016	REPLACES DOCUMENT: 187-UM-R2, 3064-MM-R4 Gonioscopy
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 3/20/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

E13.3291	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye
E13.3292	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye
E13.3293	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral
E13.3311	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye
E13.3312	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye
E13.3313	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral
E13.3391	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye
E13.3392	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye
E13.3393	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral
E13.3411	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye
E13.3412	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye
E13.3413	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral
E13.3491	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye
E13.3492	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye
E13.3493	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral
E13.3511	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye
E13.3512	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Gonioscopy
PAGE: 17 of 28	REFERENCE NUMBER: OC.UM.CP.0031
EFFECTIVE DATE: 10/01/2016	REPLACES DOCUMENT: 187-UM-R2, 3064-MM-R4 Gonioscopy
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 3/20/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

E13.3513	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral
E13.3521	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye
E13.3522	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye
E13.3523	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral
E13.3531	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye
E13.3532	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye
E13.3533	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral
E13.3541	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye
E13.3542	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye
E13.3543	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral
E13.3551	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, right eye
E13.3552	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, left eye

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Gonioscopy
PAGE: 18 of 28	REFERENCE NUMBER: OC.UM.CP.0031
EFFECTIVE DATE: 10/01/2016	REPLACES DOCUMENT: 187-UM-R2, 3064-MM-R4 Gonioscopy
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 3/20/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

E13.3553	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, bilateral
E13.3591	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye
E13.3592	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye
E13.3593	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral
E13.37X1	Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, right eye
E13.37X2	Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, left eye
E13.37X3	Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral
H20.011	Primary iridocyclitis right eye
H20.012	Primary iridocyclitis left eye
H20.013	Primary iridocyclitis bilateral
H20.021	Recurrent acute iridocyclitis right eye
H20.022	Recurrent acute iridocyclitis left eye
H20.023	Recurrent acute iridocyclitis bilateral
H20.031	Secondary infectious iridocyclitis right eye
H20.032	Secondary infectious iridocyclitis left eye
H20.033	Secondary infectious iridocyclitis bilateral
H20.041	Secondary noninfectious iridocyclitis right eye
H20.042	Secondary noninfectious iridocyclitis left eye
H20.043	Secondary noninfectious iridocyclitis bilateral
H20.051	Hypopyon right eye
H20.052	Hypopyon left eye
H20.053	Hypopyon bilateral
H20.11	Chronic iridocyclitis right eye
H20.12	Chronic iridocyclitis left eye
H20.13	Chronic iridocyclitis bilateral
H20.21	Lens-induced iridocyclitis right eye
H20.22	Lens-induced iridocyclitis left eye

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Gonioscopy
PAGE: 19 of 28	REFERENCE NUMBER: OC.UM.CP.0031
EFFECTIVE DATE: 10/01/2016	REPLACES DOCUMENT: 187-UM-R2, 3064-MM-R4 Gonioscopy
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 3/20/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

H20.23	Lens-induced iridocyclitis bilateral
H20.811	Fuchs' heterochromic cyclitis right eye
H20.812	Fuchs' heterochromic cyclitis left eye
H20.813	Fuchs' heterochromic cyclitis bilateral
H20.821	Vogt-Koyanagi syndrome right eye
H20.822	Vogt-Koyanagi syndrome left eye
H20.823	Vogt-Koyanagi syndrome bilateral
H21.01	Hyphema right eye
H21.02	Hyphema left eye
H21.03	Hyphema bilateral
H21.1X1	Other vascular disorders of iris and ciliary body right eye
H21.1X2	Other vascular disorders of iris and ciliary body left eye
H21.1X3	Other vascular disorders of iris and ciliary body bilateral
H21.211	Degeneration of chamber angle right eye
H21.212	Degeneration of chamber angle left eye
H21.213	Degeneration of chamber angle bilateral
H21.221	Degeneration of ciliary body right eye
H21.222	Degeneration of ciliary body left eye
H21.223	Degeneration of ciliary body bilateral
H21.231	Degeneration of iris (pigmentary) right eye
H21.232	Degeneration of iris (pigmentary) left eye
H21.233	Degeneration of iris (pigmentary) bilateral
H21.241	Degeneration of pupillary margin right eye
H21.242	Degeneration of pupillary margin left eye
H21.243	Degeneration of pupillary margin bilateral
H21.251	Iridoschisis right eye
H21.252	Iridoschisis left eye
H21.253	Iridoschisis bilateral
H21.261	Iris atrophy (essential) (progressive) right eye
H21.262	Iris atrophy (essential) (progressive) left eye
H21.263	Iris atrophy (essential) (progressive) bilateral
H21.271	Miotic pupillary cyst right eye
H21.272	Miotic pupillary cyst left eye

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Gonioscopy
PAGE: 20 of 28	REFERENCE NUMBER: OC.UM.CP.0031
EFFECTIVE DATE: 10/01/2016	REPLACES DOCUMENT: 187-UM-R2, 3064-MM-R4 Gonioscopy
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 3/20/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

H21.273	Miotic pupillary cyst bilateral
H23.531	Iridodialysis, right eye
H23.532	Iridodialysis, left eye
H23.533	Iridodialysis, bilateral
H27.01	Aphakia right eye
H27.02	Aphakia left eye
H27.03	Aphakia bilateral
H27.111	Subluxation of lens right eye
H27.112	Subluxation of lens left eye
H27.113	Subluxation of lens bilateral
H27.121	Anterior dislocation of lens right eye
H27.122	Anterior dislocation of lens left eye
H27.123	Anterior dislocation of lens bilateral
H27.131	Posterior dislocation of lens right eye
H27.132	Posterior dislocation of lens left eye
H27.133	Posterior dislocation of lens bilateral
H34.01	Transient retinal artery occlusion, right eye
H34.02	Transient retinal artery occlusion, left eye
H34.03	Transient retinal artery occlusion, bilateral
H34.11	Central retinal artery occlusion, right eye
H34.12	Central retinal artery occlusion, left eye
H34.13	Central retinal artery occlusion, bilateral
H34.211	Partial retinal artery occlusion, right eye
H34.212	Partial retinal artery occlusion, left eye
H34.213	Partial retinal artery occlusion, bilateral
H34.231	Retinal artery branch occlusion, right eye
H34.232	Retinal artery branch occlusion, left eye
H34.233	Retinal artery branch occlusion, bilateral
H34.8110	Central retinal vein occlusion, right eye, with macular edema
H34.8111	Central retinal vein occlusion, right eye, with retinal neovascularization
H34.8112	Central retinal vein occlusion, right eye, stable
H34.8120	Central retinal vein occlusion, left eye, with macular edema

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Gonioscopy
PAGE: 21 of 28	REFERENCE NUMBER: OC.UM.CP.0031
EFFECTIVE DATE: 10/01/2016	REPLACES DOCUMENT: 187-UM-R2, 3064-MM-R4 Gonioscopy
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 3/20/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

H34.8121	Central retinal vein occlusion, left eye with retinal neovascularization
H34.8122	Central retinal vein occlusion, left eye, stable
H34.8130	Central retinal vein occlusion, bilateral, with macular edema
H34.8131	Central retinal vein occlusion, bilateral, with retinal neovascularization
H34.8132	Central retinal vein occlusion, bilateral, stable
H34.821	Venous engorgement, right eye
H34.822	Venous engorgement, left eye
H34.823	Venous engorgement, bilateral
H34.8310	Tributary (branch) retinal vein occlusion, right eye, with macular edema
H34.8311	Tributary (branch) retinal vein occlusion, right eye, with retinal neovascularization
H34.8312	Tributary (branch) retinal vein occlusion, right eye, stable
H34.8320	Tributary (branch) retinal vein occlusion, left eye, with macular edema
H34.8321	Tributary (branch) retinal vein occlusion, left eye, with retinal neovascularization
H34.8322	Tributary (branch) retinal vein occlusion, left eye, stable
H34.8330	Tributary (branch) retinal vein occlusion, bilateral, with macular edema
H34.8331	Tributary (branch) retinal vein occlusion, bilateral, with retinal neovascularization
H34.8332	Tributary (branch) retinal vein occlusion, bilateral, stable
H35.011	Changes in retinal vascular appearance, right eye
H35.012	Changes in retinal vascular appearance, left eye
H35.013	Changes in retinal vascular appearance, bilateral
H35.021	Exudative retinopathy, right eye
H35.022	Exudative retinopathy, left eye
H35.023	Exudative retinopathy, bilateral
H35.031	Hypertensive retinopathy, right eye
H35.032	Hypertensive retinopathy, left eye
H35.033	Hypertensive retinopathy, bilateral

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Gonioscopy
PAGE: 22 of 28	REFERENCE NUMBER: OC.UM.CP.0031
EFFECTIVE DATE: 10/01/2016	REPLACES DOCUMENT: 187-UM-R2, 3064-MM-R4 Gonioscopy
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 3/20/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

H35.041	Retinal micro-aneurysms, unspecified, right eye
H35.042	Retinal micro-aneurysms, unspecified, left eye
H35.043	Retinal micro-aneurysms, unspecified, bilateral
H35.051	Retinal neovascularization, unspecified, right eye
H35.052	Retinal neovascularization, unspecified, left eye
H35.053	Retinal neovascularization, unspecified, bilateral
H35.061	Retinal vasculitis, right eye
H35.062	Retinal vasculitis, left eye
H35.063	Retinal vasculitis, bilateral
H35.071	Retinal telangiectasis, right eye
H35.072	Retinal telangiectasis, left eye
H35.073	Retinal telangiectasis, bilateral
H35.09	Other intraretinal microvascular abnormalities
H40.011	Open angle with borderline findings, low risk, right eye
H40.012	Open angle with borderline findings, low risk, left eye
H40.013	Open angle with borderline findings, low risk, bilateral
H40.021	Open angle with borderline findings, high risk, right eye
H40.022	Open angle with borderline findings, high risk, left eye
H40.023	Open angle with borderline findings, high risk, bilateral
H40.031	Anatomical narrow angle, right eye
H40.032	Anatomical narrow angle, left eye
H40.033	Anatomical narrow angle, bilateral
H40.041	Steroid responder, right eye
H40.042	Steroid responder, left eye
H40.043	Steroid responder, bilateral
H40.051	Ocular hypertension, right eye
H40.052	Ocular hypertension, left eye
H40.053	Ocular hypertension, bilateral
H40.061	Primary angle closure without glaucoma damage, right eye
H40.062	Primary angle closure without glaucoma damage, left eye
H40.063	Primary angle closure without glaucoma damage, bilateral
H40.1111	Primary open-angle glaucoma, right eye, mild stage
H40.1112	Primary open-angle glaucoma, right eye, moderate stage

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Gonioscopy
PAGE: 23 of 28	REFERENCE NUMBER: OC.UM.CP.0031
EFFECTIVE DATE: 10/01/2016	REPLACES DOCUMENT: 187-UM-R2, 3064-MM-R4 Gonioscopy
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 3/20/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

H40.1113	Primary open-angle glaucoma, right eye, severe stage
H40.1121	Primary open-angle glaucoma, left eye, mild stage
H40.1122	Primary open-angle glaucoma, left eye, moderate stage
H40.1123	Primary open-angle glaucoma, left eye, severe stage
H40.1131	Primary open-angle glaucoma, bilateral, mild stage
H40.1132	Primary open-angle glaucoma, bilateral, moderate stage
H40.1133	Primary open-angle glaucoma, bilateral, severe stage
H40.1211	Low-tension glaucoma, right eye, mild stage
H40.1212	Low-tension glaucoma, right eye, moderate stage
H40.1213	Low-tension glaucoma, right eye, severe stage
H40.1221	Low-tension glaucoma, left eye, mild stage
H40.1222	Low-tension glaucoma, left eye, moderate stage
H40.1223	Low-tension glaucoma, left eye, severe stage
H40.1231	Low-tension glaucoma, bilateral, mild stage
H40.1232	Low-tension glaucoma, bilateral, moderate stage
H40.1233	Low-tension glaucoma, bilateral, severe stage
H40.1311	Pigmentary glaucoma, right eye, mild stage
H40.1312	Pigmentary glaucoma, right eye, moderate stage
H40.1313	Pigmentary glaucoma, right eye, severe stage
H40.1321	Pigmentary glaucoma, left eye, mild stage
H40.1322	Pigmentary glaucoma, left eye, moderate stage
H40.1323	Pigmentary glaucoma, left eye, severe stage
H40.1331	Pigmentary glaucoma, bilateral, mild stage
H40.1332	Pigmentary glaucoma, bilateral, moderate stage
H40.1333	Pigmentary glaucoma, bilateral, severe stage
H40.1411	Capsular glaucoma with pseudoexfoliation of lens, right eye, mild stage
H40.1412	Capsular glaucoma with pseudoexfoliation of lens, right eye, moderate stage
H40.1413	Capsular glaucoma with pseudoexfoliation of lens, right eye, severe stage
H40.1421	Capsular glaucoma with pseudoexfoliation of lens, left eye, mild stage

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Gonioscopy
PAGE: 24 of 28	REFERENCE NUMBER: OC.UM.CP.0031
EFFECTIVE DATE: 10/01/2016	REPLACES DOCUMENT: 187-UM-R2, 3064-MM-R4 Gonioscopy
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 3/20/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

H40.1422	Capsular glaucoma with pseudoexfoliation of lens, left eye, moderate stage
H40.1423	Capsular glaucoma with pseudoexfoliation of lens, left eye, severe stage
H40.1431	Capsular glaucoma with pseudoexfoliation of lens, bilateral, mild stage
H40.1432	Capsular glaucoma with pseudoexfoliation of lens, bilateral, moderate stage
H40.1433	Capsular glaucoma with pseudoexfoliation of lens, bilateral, severe stage
H40.151	Residual stage of open-angle glaucoma, right eye
H40.152	Residual stage of open-angle glaucoma, left eye
H40.153	Residual stage of open-angle glaucoma, bilateral
H40.211	Acute angle-closure glaucoma, right eye
H40.212	Acute angle-closure glaucoma, left eye
H40.213	Acute angle-closure glaucoma, bilateral
H40.2211	Chronic angle-closure glaucoma, right eye, mild stage
H40.2212	Chronic angle-closure glaucoma, right eye, moderate stage
H40.2213	Chronic angle-closure glaucoma, right eye, severe stage
H40.2221	Chronic angle-closure glaucoma, left eye, mild stage
H40.2222	Chronic angle-closure glaucoma, left eye, moderate stage
H40.2223	Chronic angle-closure glaucoma, left eye, severe stage
H40.2231	Chronic angle-closure glaucoma, bilateral, mild stage
H40.2232	Chronic angle-closure glaucoma, bilateral, moderate stage
H40.2233	Chronic angle-closure glaucoma, bilateral, severe stage
H40.231	Intermittent angle-closure glaucoma, right eye
H40.232	Intermittent angle-closure glaucoma, left eye
H40.233	Intermittent angle-closure glaucoma, bilateral
H40.241	Residual stage of angle-closure glaucoma, right eye
H40.242	Residual stage of angle-closure glaucoma, left eye
H40.243	Residual stage of angle-closure glaucoma, bilateral
H40.31X1	Glaucoma secondary to eye trauma, right eye, mild stage
H40.31X2	Glaucoma secondary to eye trauma, right eye, moderate stage

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Gonioscopy
PAGE: 25 of 28	REFERENCE NUMBER: OC.UM.CP.0031
EFFECTIVE DATE: 10/01/2016	REPLACES DOCUMENT: 187-UM-R2, 3064-MM-R4 Gonioscopy
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 3/20/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

H40.31X3	Glaucoma secondary to eye trauma, right eye, severe stage
H40.32X1	Glaucoma secondary to eye trauma, left eye, mild stage
H40.32X2	Glaucoma secondary to eye trauma, left eye, moderate stage
H40.32X3	Glaucoma secondary to eye trauma, left eye, severe stage
H40.33X1	Glaucoma secondary to eye trauma, bilateral, mild stage
H40.33X2	Glaucoma secondary to eye trauma, bilateral, moderate stage
H40.33X3	Glaucoma secondary to eye trauma, bilateral, severe stage
H40.41X1	Glaucoma secondary to eye inflammation, right eye, mild stage
H40.41X2	Glaucoma secondary to eye inflammation, right eye moderate stage
H40.41X3	Glaucoma secondary to eye inflammation, right eye, severe stage
H40.42X1	Glaucoma secondary to eye inflammation left eye mild stage
H40.42X2	Glaucoma secondary to eye inflammation, left eye, moderate stage
H40.42X3	Glaucoma secondary to eye inflammation left eye severe stage
H40.43X1	Glaucoma secondary to eye inflammation, bilateral, mild stage
H40.43X2	Glaucoma secondary to eye inflammation bilateral moderate stage
H40.43X3	Glaucoma secondary to eye inflammation, bilateral, severe stage
H40.51X1	Glaucoma secondary to other eye disorders, right eye, mild stage
H40.51X2	Glaucoma secondary to other eye disorders, right eye, moderate stage
H40.51X3	Glaucoma secondary to other eye disorders, right eye, severe stage
H40.52X1	Glaucoma secondary to other eye disorders, left eye, mild stage
H40.52X2	Glaucoma secondary to other eye disorders, left eye, moderate stage
H40.52X3	Glaucoma secondary to other eye disorders, left eye, severe stage
H40.53X1	Glaucoma secondary to other eye disorders, bilateral, mild stage
H40.53X2	Glaucoma secondary to other eye disorders, bilateral, moderate stage
H40.53X3	Glaucoma secondary to other eye disorders, bilateral, severe stage
H40.61X1	Glaucoma secondary to drugs, right eye, mild stage
H40.61X2	Glaucoma secondary to drugs, right eye, moderate stage

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Gonioscopy
PAGE: 26 of 28	REFERENCE NUMBER: OC.UM.CP.0031
EFFECTIVE DATE: 10/01/2016	REPLACES DOCUMENT: 187-UM-R2, 3064-MM-R4 Gonioscopy
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 3/20/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

H40.61X3	Glaucoma secondary to drugs, right eye, severe stage
H40.62X1	Glaucoma secondary to drugs, left eye, mild stage
H40.62X2	Glaucoma secondary to drugs, left eye, moderate stage
H40.62X3	Glaucoma secondary to drugs, left eye, severe stage
H40.63X1	Glaucoma secondary to drugs, bilateral, mild stage
H40.63X2	Glaucoma secondary to drugs, bilateral, moderate stage
H40.63X3	Glaucoma secondary to drugs, bilateral, severe stage
H40.811	Glaucoma with increased episcleral venous pressure, right eye
H40.812	Glaucoma with increased episcleral venous pressure, left eye
H40.813	Glaucoma with increased episcleral venous pressure, bilateral
H40.821	Hypersecretion glaucoma, right eye
H40.822	Hypersecretion glaucoma, left eye
H40.823	Hypersecretion glaucoma, bilateral
H40.831	Aqueous misdirection, right eye
H40.832	Aqueous misdirection, left eye
H40.833	Aqueous misdirection, bilateral
H44.411	Flat anterior chamber hypotony of right eye
H44.412	Flat anterior chamber hypotony of left eye
H44.413	Flat anterior chamber hypotony bilateral
H44.421	Hypotony of right eye due to ocular fistula
H44.422	Hypotony of left eye due to ocular fistula
H44.423	Hypotony of bilateral eyes due to ocular fistula
H44.431	Hypotony of right eye due to other ocular disorders
H44.432	Hypotony of left eye due to other ocular disorders
H44.433	Hypotony of eye due to other ocular disorders, bilateral
H44.441	Primary hypotony of right eye
H44.442	Primary hypotony of left eye
H44.443	Primary hypotony bilateral
H44.601	Unspecified retained (old) intraocular foreign body, magnetic, right eye
H44.602	Unspecified retained (old) intraocular foreign body, magnetic, left eye

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Gonioscopy
PAGE: 27 of 28	REFERENCE NUMBER: OC.UM.CP.0031
EFFECTIVE DATE: 10/01/2016	REPLACES DOCUMENT: 187-UM-R2, 3064-MM-R4 Gonioscopy
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 3/20/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

H44.603	Unspecified retained (old) intraocular foreign body, magnetic bilateral
H44.701	Unspecified retained (old) intraocular foreign body nonmagnetic right eye
H44.702	Unspecified retained (old) intraocular foreign body nonmagnetic left eye
H44.703	Unspecified retained (old) intraocular foreign body nonmagnetic bilateral
Q15.0	Congenital glaucoma
S05.11XA	Contusion of eyeball and orbital tissues, right eye, initial encounter
S05.11XD	Contusion of eyeball and orbital tissues, right eye, subsequent encounter
S05.11XS	Contusion of eyeball and orbital tissues, right eye, sequela
S05.12XA	Contusion of eyeball and orbital tissues, left eye, initial encounter
S05.12XD	Contusion of eyeball and orbital tissues, left eye, subsequent encounter
S05.12XS	Contusion of eyeball and orbital tissues, sequela
S05.51XA	Penetrating wound with foreign body of right eyeball initial encounter
S05.51XD	Penetrating wound with foreign body of right eyeball subsequent encounter
S05.51XS	Penetrating wound with foreign body of right eyeball sequela
S05.52XA	Penetrating wound with foreign body of left eyeball initial encounter
S05.52XD	Penetrating wound with foreign body of left eyeball subsequent encounter
S05.52XS	Penetrating wound with foreign body of left eyeball sequela
S05.61XA	Penetrating wound without foreign body of right eye initial encounter
S05.61XD	Penetrating wound without foreign body of right eye subsequent encounter
S05.61XS	Penetrating wound without foreign body of right eye sequela

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Gonioscopy
PAGE: 28 of 28	REFERENCE NUMBER: OC.UM.CP.0031
EFFECTIVE DATE: 10/01/2016	REPLACES DOCUMENT: 187-UM-R2, 3064-MM-R4 Gonioscopy
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 3/20/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

S05.62XA	Penetrating wound without foreign body of left eye initial encounter
S05.62XD	Penetrating wound without foreign body of left eye subsequent encounter
S05.62XS	Penetrating wound without foreign body of left eye sequela

REVIEW/REVISION LOG

Notes	Date
Update medical indications.	03/2018
Updated diagnoses as medical indications; updated references	01/2018
Removed unspecified diagnoses from medical indications, updated diagnoses based on ICD-10 update and removed Attachment A.	12/2016
Corrected ICD-10 diagnosis codes	05/2016
Updated medical indications; updated diagnoses to ICD-10, rebranded to Envolve Benefit Options (EBO)	12/2015
Addition of diagnoses for medical necessity; addition of Attachment A with ICD9/ICD10 code crosswalk	12/2014
Annual review	12/2013